Pfizer’s alopecia drug for teens and adults approved by FDA

Breaking News

Pfizer Inc.

said late Friday that its drug ritlecitinib, sold under the brand name of Litfulo, has been approved by the U.S. Food and Drug Administration to treat adults and teens suffering from severe alopecia areata. It would be the first and only treatment for the autoimmune illness approved for patients as young as 12, the pharma giant said. Shares of Pfizer edged lower in after-hours trading Friday after ending the regular trading day down 1.1%.

Original Post

Articles You May Like

Gold Fails to Hold $2,000; EUR/USD Rises on Improved Economic Sentiment
American Airlines works with startup to reduce CO2 by storing plant bricks
Opinion: Why is everybody suddenly talking about defined-benefit plans?
How to Succeed on Airbnb in 2024
Why Stocks Are a Gift that Keeps on Giving

Leave a Reply

Your email address will not be published. Required fields are marked *